US healthcare stocks struggle in 2025 due to government policies, sparking interest from bargain hunters as valuations reach ...

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Covenant Health is now offering CAR T-cell therapy at the Joe Arrington Cancer Research & Treatment Center, marking a major ...

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...

Key Points Prime Medicine posted GAAP revenue of $1.1 million, missing analyst expectations by over 70% (GAAP). Reported net loss (GAAP) narrowed to $52.6 million, driven by reduced research and ...

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

Even though Bristol-Myers Squibb Company's ( NYSE:BMY ) recent earnings release was robust, the market didn't seem ...